Characterization of novel splicing variants of the mouse MCF-2 (DBL) proto-oncogene. 2003

Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
Department of Rheumatology, Faculty of Health Sciences, School of Medicine, Kobe University, Kobe 654-0142, Japan.

MCF-2 (DBL) proto-oncogene is a prototype guanine nucleotide exchange factor (GEF) that modulates Rho GTPases such as Rho, Rac, and Cdc42. Although the partial sequence of mouse MCF-2 has been determined, its full-length cDNA and biochemical functions had not been elucidated. We isolated the complete mouse MCF-2 cDNA and obtained recombinant functional protein. Homology between the mouse and human MCF-2 (DBL) cDNAs is 75.08% identity and between the mouse and human amino acid sequences 74.52% identity. Analysis of tissue distribution showed that mouse MCF-2 mRNA is expressed in brain, kidney, intestine, and testis. The brain-specific transcript is an alternatively spliced derivative that omits the 48bp exon 11. A similar alternatively spliced mRNA product is also found in humans (DBL). Guanine nucleotide exchange activities of the testis-expressed mouse Mcf-2 and human Dbl were analyzed using RhoA, Rac1, and Cdc42 as substrates. RhoA and Cdc42 were activated similarly by both gene products, but Rac1 was activated only by the mouse product. The brain-specific Mcf-2 gene product, and its human counterpart, was less active than the respective testis-specific products. This indicates that the element encoded by the 48bp exon missing in the brain transcripts is necessary for full GEF activity. This report provides fundamental data on the structure of Mcf-2, which regulates a variety of cellular signaling pathways.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
December 2002, Biochemical and biophysical research communications,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
December 2012, Oncology reports,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
November 1995, Oncogene,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
July 1989, Oncogene,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
June 1988, Oncogene,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
January 1990, Journal of neurosurgical sciences,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
March 2014, Gene,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
October 1999, FEBS letters,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
January 2001, Cytogenetics and cell genetics,
Koichiro Komai, and Naoko Mukae-Sakairi, and Michinori Kitagawa, and Shunichi Shiozawa
June 2005, The Journal of biological chemistry,
Copied contents to your clipboard!